Ocular changes induced by drugs commonly used in dermatology

被引:14
作者
Turno-Krecicka, Anna [1 ]
Grzybowski, Andrzej [2 ,3 ]
Misiuk-Hojlo, Marta [1 ]
Patryn, Eliza [4 ]
Czajor, Karolina [1 ]
Nita, Malgorzata [5 ]
机构
[1] Wroclaw Med Univ, Dept & Clin Ophthalmol, Ul Borowska 213, PL-50556 Wroclaw, Poland
[2] Poznan City Hosp, Dept Ophthalmol, Ul Szwajcarska 3, PL-61285 Poznan, Poland
[3] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland
[4] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[5] Domest & Specialized Med Ctr Dilmed, Ul Bohaterow Monte Cassino 3, PL-40231 Katowice, Poland
关键词
ATOPIC-DERMATITIS; ISOTRETINOIN THERAPY; ADRENAL SUPPRESSION; ANTIMALARIAL-DRUGS; HYDROXYCHLOROQUINE; CHLOROQUINE; CORTICOSTEROIDS; CATARACTS; GLAUCOMA; COMPLICATIONS;
D O I
10.1016/j.clindermatol.2015.11.012
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The use of many drugs in dermatologic diseases may cause ocular side effects. Some may regress after discontinuation of the therapy, but others persist or progress even after the cessation of treatment. This review presents four groups of commonly prescribed drugs-antimalarial medicines, glucocorticoids, retinoids, and psoralens + ultraviolet A (UVA) therapy-and discusses their possible ocular side effects. The most significant complication of antimalarial drugs is retinopathy with the risk of permanent visual impairment. There are different recommendations for screening for this drug-related retinopathy. The most important ocular manifestations of steroid management are irreversible optic nerve damage in "steroid responders" (steroid glaucoma) and cataract. Some other side effects may disappear after discontinuation of the therapy. Retinoid-induced ocular side effects include ocular surface disease as well as retinal dysfunction. It is recommended to modify the therapy when night blindness occurs or after the decrease of color vision. Protective eyewear is sufficient to avoid ocular surface problems during psoralen + UVA therapy. The knowledge of screening schemes and closer cooperation between physicians may decrease the risk of serious or irreversible ocular side effects. (C) 2016 Published by Elsevier Inc.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 83 条
[1]   CUTANEOUS AND OCULAR SIDE-EFFECTS OF PUVA PHOTOCHEMOTHERAPY - A 10-YEAR FOLLOW-UP-STUDY [J].
ABDULLAH, AN ;
KECZKES, K .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1989, 14 (06) :421-424
[2]   OCULAR COMPLICATIONS OF SYSTEMIC STEROID AFTER RENAL-TRANSPLANTATION AND THEIR ASSOCIATION WITH HLA [J].
ADHIKARY, HP ;
SELLS, RA ;
BASU, PK .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1982, 66 (05) :290-291
[3]   EXTENSIVE VISUAL-LOSS WITH TOPICAL FACIAL STEROIDS [J].
AGGARWAL, RK ;
POTAMITIS, T ;
CHONG, NHV ;
GUARRO, M ;
SHAH, P ;
KHETERPAL, S .
EYE, 1993, 7 :664-666
[4]  
[Anonymous], 2013, J OPHTHALMOL
[5]   Cataracts in Atopic Dermatitis A Case Presentation and Review of the Literature [J].
Bair, Brooke ;
Dodd, John ;
Heidelberg, Karen ;
Krach, Kent .
ARCHIVES OF DERMATOLOGY, 2011, 147 (05) :585-588
[6]   OPHTHALMOLOGIC CONSIDERATIONS AND TESTING IN PATIENTS RECEIVING LONG-TERM ANTI-MALARIAL THERAPY [J].
BERNSTEIN, HN .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (1A) :25-34
[7]   A RETROSPECTIVE STUDY OF OCULAR FINDINGS IN PATIENTS TREATED WITH PUVA [J].
BOUKES, RJ ;
VANBALEN, ATM ;
BRUYNZEEL, DP .
DOCUMENTA OPHTHALMOLOGICA, 1985, 59 (01) :11-19
[8]   Central serous chorioretinopathy and glucocorticoids [J].
Bouzas, EA ;
Karadimas, P ;
Pournaras, CJ .
SURVEY OF OPHTHALMOLOGY, 2002, 47 (05) :431-448
[9]  
CALZAVARAPINTON PG, 1994, ACTA DERM-VENEREOL, V74, P164
[10]  
CAMBIAGGI A, 1957, ARCH OPHTHALMOL-CHIC, V57, P451